OS Therapies Inc (OSTX): Insider Trading, Congress Trades & Research | Tormere

OSTX

$1.15-0.86%visit website

OS Therapies Inc

Market Cap

$53M

Live price × SEC shares (Aug 12, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

-0.51

26mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	3,755	8,797	7,352	6,074	25,978
Operating income	(6,880)	(11,988)	(10,168)	(8,576)	(37,611)
Interest expense			75.3	5.6
Net income	(6,880)	(13,461)	(10,397)	(8,632)	(39,370)
EPS (basic) ($)	(0.21)		(0.27)	(0.20)	—
EPS (diluted) ($)	(0.21)		(0.27)	(0.20)	—
Weighted avg. shares (diluted)	31,957		38,675	43,904

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 10 more quarters, back to Mar 2023, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

At $1.25 a share, OS Therapies (OSTX) grants Olivier Roger Jarry options on 300,000 shares.

Stock Titan · 2026-10-31

CFO receives 300,000 OS Therapies (OSTX) options with a $1.25 exercise price per share.

Stock Titan · 2026-10-31

300,000 options at $1.25 go to OS Therapies (OSTX) commercial chief Kerry M. Clem.

Stock Titan · 2026-10-31

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

Yahoo · 2026-10-19

OS Therapies Inc. (OSTX) Raises ~$7.2M From Warrant Exercises

TradingView · 2026-10-19

OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History

Yahoo Finance · 2026-10-12

Rubenstein Public Relations Named Agency of Record for OS Therapies

Yahoo · 2026-10-08

OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

Yahoo · 2026-10-07

OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma

Benzinga · 2026-10-07

OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

Benzinga · 2026-10-06

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

Yahoo · 2026-10-06

OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control

Benzinga · 2026-10-06

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

Yahoo Finance · 2026-10-01

OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

Yahoo Finance · 2026-09-24

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

Yahoo Finance · 2026-09-21

Informational purposes only, not investment advice.